Shafiee G, Ostovar A, Heshmat R, Darabi H, Sharifi F, Raeisi A, Mehrdad N, et al. Bushehr Elderly Health (BEH) programme: study protocol and design of musculoskeletal system and cognitive function (stage II). BMJ Open. 2017;7(8): e013606.
Article PubMed PubMed Central Google Scholar
Xiao PL, Cui AY, Hsu CJ, Peng R, Jiang N, Xu XH, Ma YG, et al. Global, regional prevalence, and risk factors of osteoporosis according to the World Health Organization diagnostic criteria: a systematic review and meta-analysis. Osteoporos Int. 2022;33(10):2137–53.
Salari N, Ghasemi H, Mohammadi L, Larti M, Kiaei A, Hemmati M, Shohaimi S, et al. The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res. 2021;16(1):1–20.
Ström O, Borgström F, Kanis JA, Compston J, Cooper C, McCloskey EV, et al. Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2011;6:59–155. https://doi.org/10.1007/s11657-011-0060-1.
Yuan S, Larsson SC. Epidemiology of sarcopenia: Prevalence, risk factors, and consequences. Metabolism. 2023;144:155533. https://doi.org/10.1016/j.metabol.2023.155533.
Panday K, Gona A, Humphrey MB. Medication-induced osteoporosis: screening and treatment strategies. Therapeutic Adv Musculoskelet Disease. 2014;6(5):185–202.
Pouresmaeili F, Kamalidehghan B, Kamarehei M, Goh YM. A comprehensive overview on osteoporosis and its risk factors. Ther Clin Risk Manag. 2018;14:2029–49. https://doi.org/10.2147/TCRM.S138000.
Zawada A, Ratajczak AE, Rychter AM, Szymczak-Tomczak A, Dobrowolska A, Krela-Kaźmierczak I. Treatment of diabetes and osteoporosis—a reciprocal risk. Biomedicines. 2022;10(9): 2191.
Article CAS PubMed PubMed Central Google Scholar
Bowles SK. Drug-induced osteoporosis. In: PSAP women’s and men’s health. Lenexa: American College of Clinical Pharmacy; 2010. p. 203–24.
Tournadre A, Vial G, Capel F, Soubrier M, Boirie Y. Sarcopenia Joint Bone Spine. 2019;86(3):309–14.
Feng L, Gao Q, Hu K, Wu M, Wang Z, Chen F, Mei F, et al. Prevalence and risk factors of Sarcopenia in patients with Diabetes: a meta-analysis. J Clin Endocrinol Metabolism. 2022;107(5):1470–83.
Campins L, Camps M, Riera A, Pleguezuelos E, Yebenes JC, Serra-Prat M. Oral Drugs related with muscle wasting and sarcopenia. A review. Pharmacology. 2017;99(1–2):1–8.
Article CAS PubMed Google Scholar
Kirk B, Zanker J, Duque G. Osteosarcopenia: epidemiology, diagnosis, and treatment—facts and numbers. J Cachexia Sarcopenia Muscle. 2020;11(3):609–18.
Article PubMed PubMed Central Google Scholar
Fahimfar N, Zahedi Tajrishi F, Gharibzadeh S, Shafiee G, Tanha K, Heshmat R, Nabipour I. Prevalence of osteosarcopenia and its association with cardiovascular risk factors in Iranian older people: Bushehr Elderly Health (BEH) Program. Calcif Tissue Int. 2020;106:364–70.
Article CAS PubMed Google Scholar
Salech F, Marquez C, Lera L, Angel B, Saguez R, Albala C. Osteosarcopenia predicts falls, fractures, and mortality in Chilean community-dwelling older adults. J Am Med Dir Assoc. 2021;22(4):853–8.
Huang T, Li C, Chen F, Xie D, Yang C, Chen Y, Wang J, et al. Prevalence and risk factors of osteosarcopenia: a systematic review and meta-analysis. BMC Geriatr. 2023;23(1):1–15.
Liu J, Yu D, Xu M, Feng R, Sun Y, Yin X, Lai H, et al. β-Cell function is associated with osteosarcopenia in middle-aged and older nonobese patients with type 2 Diabetes: a cross-sectional study. Open Med. 2021;16(1):1583–90.
Jackuliak P, Kužma M, Payer J. Effect of antidiabetic treatment on bone. Physiol Res. 2019;68(Suppl 2):S107–20. https://doi.org/10.33549/physiolres.934297.
Kalaitzoglou E, Fowlkes JL, Popescu I, Thrailkill KM. Diabetes pharmacotherapy and effects on the musculoskeletal system. Diab/Metab Res Rev. 2019;35(2): e3100.
Jiating L, Buyun J, Yinchang Z. Role of metformin on osteoblast differentiation in type 2 diabetes. Biomed Res Int. 2019;2019:9203934. https://doi.org/10.1155/2019/9203934.
Tricarico D, Mele A, Camerino GM, Bottinelli R, Brocca L, Frigeri A, ..., Camerino DC. The KATP channel is a molecular sensor of atrophy in skeletal muscle. J Physiol. 2010; 588(5):773–784.
Wu CN, Tien KJ. The impact of antidiabetic agents on sarcopenia in type 2 diabetes: A literature review. J Diabetes Res. 2020;2020:9368583. https://doi.org/10.1155/2020/9368583.
Esteghamati A, Larijani B, Aghajani MH, Ghaemi F, Kermanchi J, Shahrami A, Saadat M, et al. Diabetes in Iran: prospective analysis from first nationwide Diabetes report of National Program for Prevention and Control of Diabetes (NPPCD-2016). Sci Rep. 2017;7(1):13461.
Article PubMed PubMed Central Google Scholar
Ostovar A, Nabipour I, Larijani B, Heshmat R, Darabi H, Vahdat K, Ravanipour M, et al. Bushehr elderly health (BEH) Programme, phase I (cardiovascular system). BMJ Open. 2015;5(12): e009597.
Article PubMed PubMed Central Google Scholar
Khalagi K, Ansarifar A, Fahimfar N, et al. Cardio-metabolic and socio-demographic risk factors associated with dependency in basic and instrumental activities of daily living among older Iranian adults: Bushehr elderly health program. BMC Geriatr. 2021;21:172. https://doi.org/10.1186/s12877-021-02124-x.
Article PubMed PubMed Central Google Scholar
Aadahl M, Jørgensen T. Validation of a new self-report instrument for measuring physical activity. Med Sci Sports Exerc. 2003;35(7):1196–202.
Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, Sayer AA. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing. 2011;40(4):423–9.
Fathi M, Heshmat R, Ebrahimi M, Salimzadeh A, Ostovar A, Fathi A, Razi F, et al. Association between biomarkers of bone health and osteosarcopenia among Iranian older people: the Bushehr Elderly Health (BEH) program. BMC Geriatr. 2021;21:1–9.
Kanis JA, Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int. 1994;4:368–81.
Article CAS PubMed Google Scholar
Shafiee G, Heshmat R, Ostovar A, Khatami F, Fahimfar N, Arzaghi SM, Gharibzadeh S, et al. Comparison of EWGSOP-1 and EWGSOP-2 diagnostic criteria on prevalence of and risk factors for Sarcopenia among Iranian older people: the Bushehr Elderly Health (BEH) program. J Diabetes Metabolic Disorders. 2020;19:727–34.
Shafiee G, Ostovar A, Heshmat R, Keshtkar AA, Sharifi F, Shadman Z, et al. Appendicular skeletal muscle mass reference values and the peak muscle mass to identify sarcopenia among Iranian healthy population. Int J Prev Med. 2018;9:25. https://doi.org/10.4103/ijpvm.IJPVM_295_17.
Xie X, Hu L, Mi B, Xue H, Hu Y, Panayi AC, Endo Y, et al. Metformin alleviates bone loss in ovariectomized mice through inhibition of autophagy of osteoclast precursors mediated by E2F1. Cell Communication and Signaling. 2022;20(1):165.
Article CAS PubMed PubMed Central Google Scholar
Chen K, Wu R, Mo B, Yan X, Shen D, Chen M. Comparison between liraglutide alone and liraglutide in combination with insulin on osteoporotic rats and their effect on bone mineral density. J Musculoskel Neuronal Interact. 2021;21(1):142.
Ustulin M, Park SY, Choi H, Chon S, Woo JT, Rhee SY. Effect of dipeptidyl peptidase-4 inhibitors on the risk of bone fractures in a Korean population. J Korean Med Sci. 2019;34:3435).
Urbanovych A, Kryvko O. The effect of antidiabetic Drugs on the Musculoskeletal System in Women. Romanian J Diabetes Nutr Metabolic Dis. 2021;28(2):223–6.
Rajpathak SN, Fu C, Brodovicz KG, Engel SS, Lapane K. Sulfonylurea use and risk of hip fractures among elderly men and women with type 2 Diabetes. Drugs Aging. 2015;32:321–7.
Article CAS PubMed Google Scholar
Tseng CH. Metformin use is associated with a lower risk of osteoporosis/vertebral fracture in Taiwanese patients with type 2 Diabetes Mellitus. Eur J Endocrinol. 2021;184(2):299–310.
Article CAS PubMed Google Scholar
Wang LX, Wang GY, Su N, Ma J, Li YK. Effects of different doses of metformin on bone mineral density and bone metabolism in elderly male patients with type 2 Diabetes Mellitus. World J Clin Cases. 2020;8(18): 4010.
Article PubMed PubMed Central Google Scholar
Yang BR, Cha SH, Lee KE, Kim JW, Lee J, Shin KH. Effect of dipeptidyl peptidase IV inhibitors, thiazolidinedione, and sulfonylurea on osteoporosis in patients with type 2 diabetes: population-based cohort study. Osteoporos Int. 2021;32(9):1705–12. https://doi.org/10.1007/s00198-020-05801-6.
Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2007;92(4):1305–10.
Article CAS PubMed Google Scholar
De Martinis M, Sirufo MM, Polsinelli M, Placidi G, Di Silvestre D, Ginaldi L. Gender differences in osteoporosis: a single-center observational study. World J men’s Health. 2021;39(4):750.
Majumdar SR, Josse RG, Lin M, Eurich DT. Does sitagliptin affect the rate of osteoporotic fractures in type 2 Diabetes? Population-based cohort study. J Clin Endocrinol Metabolism. 2016;101(5):1963–9.
Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with Diabetes Mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia. 2005;48:1292–9.
Article CAS PubMed Google Scholar
Gilbert MP, Pratley RE. The impact of diabetes and diabetes medications on bone health. Endocr Rev. 2015;36(2):194–213.
Article CAS PubMed Google Scholar
Chen HH, Horng MH, Yeh SY, Lin IC, Yeh CJ, Muo CH, Sung FC, et al. Glycemic control with thiazolidinedione is associated with fracture of T2DM patients. PLoS ONE. 2015;10(8): e0135530.
Article PubMed PubMed Central Google Scholar
Losada-Grande E, Hawley S, Soldevila B, Martinez-Laguna D, Nogues X, Diez-Perez A, ..., Prieto-Alhambra D. Insulin use and excess fracture risk in patients with type 2 diabetes: a propensity-matched cohort analysis. Sci Rep. 2017;7(1):3781.
Chen F, Xu S, Wang Y, Chen F, Cao L, Liu T, et al. Risk factors for sarcopenia in the elderly with type 2 diabetes mellitus and the effect of metformin. J Diabetes Res. 2020;2020:3950404.
留言 (0)